News|Articles|April 1, 2026
Middle East Disruption Impacts 6.7% of Global Clinical Trials, With Phase 3 Studies Most Affected
Author(s)Pearl Steinzor
Fact checked by: Christina Mattina
Evaluation of more than 65,000 trials and 350,000 investigator sites highlights significant exposure in oncology and late-stage development.
Advertisement
Advertisement
The ongoing disruption in the Middle East is affecting a meaningful portion of global clinical research, with 6.7% of active trials and thousands of investigator sites exposed to regional instability, new insights from Phesi reveal.1
Advertisement
Advertisement